The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global connected drug delivery devices market exhibited robust growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 40% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Connected drug delivery devices are smart wireless electronic systems used to support patient supervision and counseling in home settings. They are equipped with dose reminders, adherence trackers, sensors and monitoring tools to provide instant feedback and education tools for personalized patient care. They are convenient and save costs associated with clinic-based treatment. Consequently, connected drug delivery devices are widely used in the remote monitoring of patients with asthma, diabetes, hepatitis C, hypertension, tuberculosis, multiple sclerosis, clinically isolated syndrome, chronic obstructive pulmonary disease (COPD), and liver and renal transplant recipients.
The rapidly increasing cost of medical management and the rising need to improve patient treatment outcomes are among the main factors catalyzing the demand for connected drug delivery devices. Besides this, a shift in preferences towards home-based care is also stimulating the market growth. Moreover, the rising number of individuals suffering from chronic diseases, along with the increasing emphasis on preventive care, is influencing the market positively. Furthermore, the widespread adoption of connected devices in laboratories and hospitals for maintaining electronic health records (EHR) is driving the market growth. Apart from this, several manufacturers are offering devices that can connect to apps and programs, allow data transfer, enable automated tracking, and maximize patient safety. As they also provide access to real-time patient data, connected drug delivery devices are increasingly being utilized by biopharma companies for determining adherence improvement outcomes to regulators, payers, and patients.
IMARC Group provides an analysis of the key trends in each sub-segment of the global connected drug delivery devices market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product, end user and technology.
Breakup by Product:
Breakup by End User:
Breakup by Technology:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Adherium Ltd., BioCorp Production, Cohero Health Inc. (AptarGroup Inc.), Elcam Medical ACS. Ltd, Findair Sp. z o. o., Merck KGaA, Phillips Medisize (Molex LLC), Propeller Health (Resmed Inc.), Teva Pharmaceutical Industries Ltd., and West Pharmaceutical Services Inc.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, End User, Technology, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Adherium Ltd., BioCorp Production, Cohero Health Inc. (AptarGroup Inc.), Elcam Medical ACS. Ltd, Findair Sp. z o. o., Merck KGaA, Phillips Medisize (Molex LLC), Propeller Health (Resmed Inc.), Teva Pharmaceutical Industries Ltd., and West Pharmaceutical Services Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at